Kintara Therapeutics Inc (NASDAQ: KTRA)’s stock price has increased by 13.88 compared to its previous closing price of 0.11. However, the company has seen a -2.96% decrease in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-04 that Kintara (KTRA) inks a definitive merger agreement with TuHURA for an all-stock transaction. It is expected to close in the third quarter of 2024.
Is It Worth Investing in Kintara Therapeutics Inc (NASDAQ: KTRA) Right Now?
KTRA has 36-month beta value of 0.55. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KTRA is 55.20M, and currently, short sellers hold a 1.19% ratio of that float. The average trading volume of KTRA on April 22, 2024 was 13.82M shares.
KTRA’s Market Performance
KTRA stock saw an increase of -2.96% in the past week, with a monthly gain of 34.74% and a quarterly increase of -11.45%. The volatility ratio for the week is 9.24%, and the volatility levels for the last 30 days are 13.05% for Kintara Therapeutics Inc (KTRA). The simple moving average for the last 20 days is 7.30% for KTRA stock, with a simple moving average of -93.32% for the last 200 days.
KTRA Trading at 14.67% from the 50-Day Moving Average
After a stumble in the market that brought KTRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.97% of loss for the given period.
Volatility was left at 13.05%, however, over the last 30 days, the volatility rate increased by 9.24%, as shares surge +32.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.12% upper at present.
During the last 5 trading sessions, KTRA fell by -2.96%, which changed the moving average for the period of 200-days by -97.20% in comparison to the 20-day moving average, which settled at $0.1146. In addition, Kintara Therapeutics Inc saw -28.42% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for KTRA
The total capital return value is set at -720.4. Equity return is now at value -329.00, with -179.36 for asset returns.
Currently, EBITDA for the company is -14.75 million with net debt to EBITDA at 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.63.
Conclusion
To put it simply, Kintara Therapeutics Inc (KTRA) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
